SAN FRANCISCO – Apremilast met its primary endpoint at week 32 with no new or serious safety signals among patients with moderate to severe plaque p... More »
SAN FRANCISCO – More than 80% of psoriasis patients who received ixekizumab achieved a 75% reduction in the Psoriasis Area and Severity Index score ... More »
SAN FRANCISCO – An investigational topical sebum inhibitor met its primary endpoints in a phase IIa trial, significantly reducing inflammatory and n... More »
SAN FRANCISCO – An investigational interleukin-23 inhibitor for moderate to severe plaque psoriasis achieved almost twice the PASI 90 response rate ... More »
SAN FRANCISCO – Weekly treatment with 40 mg of adalimumab yielded the strongest clinical responses in adults with moderate to severe hidradenitis su... More »
KAUAI, HAWAII – Using photodynamic therapy in place of blue-light therapy to reverse sun damage such as actinic keratosis is less expensive and asso... More »
SAN FRANCISCO– Dupilumab met its safety endpoints and significantly outperformed placebo for adults with moderate to severe atopic dermatitis, accor... More »
SAN FRANCISCO – Sometimes, salicylic acid is the right call for exfoliation, but sometimes not. Other times microdermabrasion or glycolic acid make ... More »
SAN FRANCISCO – Older white men are most at risk to die from skin cancer after organ transplants, especially if they’ve had a heart or lung transp... More »
SAN FRANCISCO – Formaldehyde has been named the American Contact Dermatitis Society Contact Allergen of the Year for 2015, Dr. David E. Cohen said i... More »